SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
MDS_23871_sm_SuppFig1.tif335KSupplementary Figure 1. ROC curve analysis. ROC analysis was conducted to compare the plasma PTX3 levels in the control and PD patients.
MDS_23871_sm_SuppFig2.tif286KSupplementary Figure 2. Correlation between the PTX3 plasma levels and the Schwab & England ADL scale and the H&Y stage in the PD patients (n=66). After adjusting for age and comorbidity, the PTX3 levels showed significant negative correlations with the Schwab & England ADL scale (r = - 0.277; p = 0.027) (A). There was no significant correlation between the PTX3 levels and the H&Y stage (r = 0.169; p = 0.183) (B).
MDS_23871_sm_SuppFig3.tif274KSupplementary Figure 3. Correlation between the plasma levels of PTX3 and the disease duration in the PD patients (n = 66). After adjusting for age and comorbidity, there was no significant correlation between the PTX3 levels and the disease duration in the PD patients (r = - 0.032, p = 0.801).
MDS_23871_sm_SuppFig4.tif267KSupplementary Figure 4. Measurement of the plasma levels of PTX3 in the control subjects (n = 41) and the PD (n = 66), MSA (n = 9) and PSP (n = 5) patients. The PTX3 plasma levels were determined by specific Sandwich ELISA. The horizontal bar in each column indicates the mean values of the PTX3 levels, with statistically significant differences between the groups indicated by the p values after adjustment for age, gender and comorbidities.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.